Meditsiiniseadmed. Riskijuhtimise rakendamine meditsiiniseadmetele

Medical devices - Application of risk management to medical devices (ISO 14971:2007, Corrected version 2007-10-01)
<table>
<thead>
<tr>
<th>EESTI STANDARDI EESSÕNA</th>
<th>NATIONAL FOREWORD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard on kinnitatud Eesti Standardikeskuse käskkirjaga ja jõustub sellekohase teate avaldamisel EVS Teatajas.</td>
<td>This standard is ratified with the order of Estonian Centre for Standardisation dated and is endorsed with the notification published in the official bulletin of the Estonian national standardisation organisation.</td>
</tr>
<tr>
<td>Standard on kättesaadav Eesti standardorganisatsioonist.</td>
<td>The standard is available from Estonian standardisation organisation.</td>
</tr>
</tbody>
</table>

ICS 11.040.01

meditsiiniseadmed, riskijuhtimine
Medical devices - Application of risk management to medical devices (ISO 14971:2007, Corrected version 2007-10-01)
Foreword

The text of ISO 14971:2007, Corrected version 2007-10-01, has been prepared by Technical Committee ISO/TC 210 “Quality management and corresponding general aspects for medical devices” of the International Organization for Standardization (ISO) and has been taken over as EN ISO 14971:2012 by Technical Committee CEN-CLC/TC 3 “Quality management and corresponding general aspects for medical devices”, the Secretariat of which is held by NEN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by January 2013, and conflicting national standards shall be withdrawn at the latest by January 2013.

This document supersedes EN ISO 14971:2009.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN [and/or CENELEC] shall not be held responsible for identifying any or all such patent rights.

This document has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association, and supports essential requirements of EU Directives 93/42/EEC on Medical Devices, 90/385/EEC on Active Implantable Medical Devices and 98/79/EC on In Vitro Diagnostic Devices.

For relationship with EU Directives, see informative Annexes ZA, ZB and ZC, which are an integral part of this document.

According to the CEN/CENELEC Internal Regulations, the national standards organisations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

Endorsement notice

The text of ISO 14971:2007, Corrected version 2007-10-01, has been approved by CEN as an EN ISO 14971:2012 without any modification.
Annex ZA
(informative)

Relationship between this European Standard and Requirements of EU Directive 93/42/EEC on Medical Devices

This European Standard has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association to provide a means of conforming to Requirements of the New Approach Directive 93/42/EEC on Medical Devices.

Within the limits of the scope of this standard (Clause 1 of EN ISO 14971:2012), compliance with the clauses of this standard confers a presumption of conformity with requirements of that Directive and associated EFTA regulations, once this standard is cited in the Official Journal of the European Union under that Directive and has been implemented as a national standard in at least one Member State. This Annex ZA explains to which requirements, under which conditions and to what extent presumption of conformity can be claimed.

Whilst only a limited number of requirements is covered just by the application of this standard, authorities in charge of medical devices strongly recommend using this standard. The standard leads, according to experience of the authorities, to a higher degree of compliance with legal obligations.

EN ISO 14971:2012 provides a process for managing risks associated with medical devices. Because this standard describes an ongoing, lifecycle process applicable in part or in all to the Essential Requirements of Directive 93/42/EEC on Medical Devices, it is – very exceptionally – not meaningful to link individual clauses of the standard to specific corresponding Essential Requirements.

Compliance with all the normative clauses in EN ISO 14971 will ensure that a process is in place to address general risk management aspects related to medical devices, which are included in the Essential Requirements. However, because this is an international standard, intended to be applicable in jurisdictions all over the world, it is not the primary goal of the standard to cover exactly any of the European Essential Requirements. Therefore, for all of the Essential Requirements, conformity is not entirely achieved by complying only with the requirements specified in this standard. Manufacturers and conformity assessment bodies will need to feed the Essential Requirements into the risk management process provided by the standard. Explanation on the correspondence of the standard and the Essential Requirements is included in Table ZA.1. Further explanation on content deviations between the standard and the ERs is provided below the table.
<table>
<thead>
<tr>
<th>Clause(s)/subclause(s) of this EN</th>
<th>Essential Requirements (ERs) of Directive 93/42/EEC</th>
<th>Qualifying remarks/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-9</td>
<td>1</td>
<td>ER 1 is not directly covered by EN ISO 14971, since the standard does not provide requirements on design and manufacture. However, the standard provides a tool to generate the information that is a necessary preliminary step for a manufacturer to demonstrate that the device is in conformity with ER 1. For content deviations, see points 1, 2, 3, 4 below.</td>
</tr>
</tbody>
</table>
| 1-9                           | 2                                                | - The second sentence of ER 2 is partly covered by 6.2. For content deviations, see points 1, 2, 3, 5, 6, 7 below.  
- The other parts of ER 2 are not directly covered by EN ISO 14971, since the standard does not provide requirements on design and construction, nor does it apply the concept of ‘safety principles’ as intended in the MDD. However, the standard provides a tool to generate the information that is a necessary preliminary step for a manufacturer to demonstrate that the device is in conformity with ER 2. |
| 1-9                           | 4                                                | ER 4 is not directly covered by EN ISO 14971, since the standard does not apply the concept of ‘safety principles’ as intended in the MDD. However, the standard provides a tool to generate the information that is a necessary preliminary step for a manufacturer to demonstrate that the device is in conformity with ER 4. |
| 1-9                           | 5                                                | ER 5 is not directly covered by EN ISO 14971, since the standard does not provide requirements on design, manufacture or packaging. However, the standard provides a tool to generate the information that is a necessary preliminary step for a manufacturer to demonstrate that the device is in conformity with ER 5. |
### Content deviations

The following aspects have been identified where the standard deviates or might be understood as deviating from the Essential Requirements:

1. **Treatment of negligible risks:**
   a) According to standard ISO 14971, the manufacturer may discard negligible risks.
   b) However, Sections 1 and 2 of Annex I to Directive 93/42/EEC require that all risks, regardless of their dimension, need to be reduced as much as possible and need to be balanced, together with all other risks, against the benefit of the device.
   c) Accordingly, the manufacturer must take all risks into account when assessing Sections 1 and 2 of Annex I to Directive 93/42/EEC.

2. **Discretionary power of manufacturers as to the acceptability of risks:**
   a) ISO 14971 seems to imply that manufacturers have the freedom to decide upon the threshold for risk acceptability and that only non-acceptable risks have to be integrated into the overall risk-benefit analysis.
   b) However, Sections 1 and 2 of Annex I to Directive 93/42/EEC require that all risks have to be reduced as far as possible and that all risks combined, regardless of any "acceptability" assessment, need to be balanced, together with all other risks, against the benefit of the device.
   c) Accordingly, the manufacturer may not apply any criteria of risk acceptability prior to applying Sections 1 and 2 of Annex I to Directive 93/42/EEC.

---

1 This is explicitly stated in D.8.2.

2 Sections 5, 6.4, 6.5, 7: reference to the criteria set-up in the management plan which is under the discretion of the manufacturer (see Sections 3.2, 3.4d)). See also D.4: "This International Standard does not specify acceptable risk. That decision is left to the manufacturer."

3 See D.6.1.
3. Risk reduction "as far as possible" versus "as low as reasonably practicable":

a) Annex D.8 to ISO 14971, referred to in 3.4, contains the concept of reducing risks "as low as reasonably practicable" (ALARP concept). The ALARP concept contains an element of economic consideration.

b) However, the first indent of Section 2 of Annex I to Directive 93/42/EEC and various particular Essential Requirements require risks to be reduced "as far as possible" without there being room for economic considerations.

c) Accordingly, manufacturers and Notified Bodies may not apply the ALARP concept with regard to economic considerations.

4. Discretion as to whether a risk-benefit analysis needs to take place:

a) 6.5 of ISO 14971 says: "If the residual risk is not judged acceptable using the criteria established in the risk management plan and further risk control is not practicable, the manufacturer may gather and review data and literature to determine if the medical benefits of the intended use outweigh the residual risk." Clause 7 of ISO 14971 says: "If the overall residual risk is not judged acceptable using the criteria established in the risk management plan, the manufacturer may gather and review data and literature to determine if the medical benefits of the intended use outweigh the overall residual risk." Both quotes imply that an overall risk-benefit analysis does not need to take place if the overall residual risk is judged acceptable when using the criteria established in the risk management plan. Equally, D.6.1 says: "A risk/benefit analysis is not required by this International Standard for every risk."

b) According to Section 1 of Annex I to Directive 93/42/EEC, an overall risk-benefit analysis must take place in any case, regardless of the application of criteria established in the management plan of the manufacturer. Furthermore, Section 6 of Annex I to Directive 93/42/EEC requires undesirable side-effects to "constitute an acceptable risk when weighed against the performance intended".

c) Accordingly, the manufacturer must undertake the risk-benefit analysis for the individual risk and the overall risk-benefit analysis (weighing all risks combined against the benefit) in all cases.

5. Discretion as to the risk control options/measures:

a) 6.2 of ISO 14971 obliges the manufacturer to "use one or more of the following risk control options in the priority order listed: (a) inherent safety by design; (b) protective measures in the medical device itself or in the manufacturing process; (c) information for safety" and leaves a discretion as to the application of these three options: shall the second or third control option still be used when the first was used? 6.4 indicates that further risk control measures do not need to be taken if, after applying one of the control options, the risk is judged acceptable according to the criteria of the risk management plan.

b) However, the second sentence of Section 2 of Annex I to Directive 93/42/EEC requests "to conform to safety principles, taking account of the generally acknowledged state of the art" and "to select the most appropriate solutions" by applying cumulatively what has been called "control options" or "control mechanisms" in the standard.

c) Accordingly, the manufacturer must apply all the "control options" and may not stop his endeavours if the first or the second control option has reduced the risk to an "acceptable level" (unless the additional control option(s) do(es) not improve the safety).

6. Deviation as to the first risk control option:

a) 6.2 of ISO 14971 obliges the manufacturer to "use one or more of the following risk control options in the priority order listed: (a) inherent safety by design …" without determining what is meant by this term.

b) However, the first indent of the second sentence of Section 2 of Annex I to Directive 93/42/EEC requires to "eliminate or reduce risks as far as possible (inherently safe design and construction)."

c) Accordingly, as the Directive is more precise than the standard, manufacturers must apply the former and cannot rely purely on the application of the standard.

7. Information of the users influencing the residual risk:

a) The residual risk is in 2.15 and in 6.4 of ISO 14971 defined as the risk remaining after application of the risk control measures. 6.2 of ISO 14971 regards "information for safety" to be a control option.
b) However, the last indent of Section 2 of Annex I to Directive 93/42/EEC says that users shall be informed about the residual risks. This indicates that, according to Annex I to Directive 93/42/EEC and contrary to the concept of the standard, the information given to the users does not reduce the (residual) risk any further.

c) Accordingly, manufacturers shall not attribute any additional risk reduction to the information given to the users.

Conformity assessment procedures

EN ISO 14971 can also be used to support the following parts of conformity assessment procedures in the European Medical Devices Directives:

− an adequate description of results of the risk analysis (included in the risk management file, see 3.5 of EN ISO 14971:2012);

− an undertaking by the manufacturer to institute and keep up to date a systematic procedure to review experience gained from devices in the post-production phase and to implement appropriate means to apply any necessary corrective action (see Clause 9 of EN ISO 14971:2012).

NOTE Other and more detailed requirements are applicable to this aspect.

WARNING — Other requirements and other EU Directives may be applicable to a product falling within the scope of this standard.
Annex ZB
(informative)

Relationship between this European Standard and Requirements of EU Directive 90/385/EEC on Active Implantable Medical Devices

This European Standard has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association to provide a means of conforming to Requirements of the New Approach Directive 90/385/EEC on Active Implantable Medical Devices.

Within the limits of the scope of this standard (Clause 1 of EN ISO 14971:2012), compliance with the clauses of this standard confers a presumption of conformity with requirements of that Directive and associated EFTA regulations, once this standard is cited in the Official Journal of the European Union under that Directive and has been implemented as a national standard in at least one Member State. This Annex ZB explains to which requirements, under which conditions and to what extent presumption of conformity can be claimed.

Whilst only a limited number of requirements is covered just by the application of this standard, authorities in charge of medical devices strongly recommend using this standard. The standard leads, according to experience of the authorities, to a higher degree of compliance with legal obligations.

EN ISO 14971:2012 provides a process for managing risks associated with medical devices. Because this standard describes an ongoing, lifecycle process applicable in part or in all to the Essential Requirements of Directive 90/385/EEC on Active Implantable Medical Devices, it is – very exceptionally – not meaningful to link individual clauses of the standard to specific corresponding Essential Requirements.

Compliance with all the normative clauses in EN ISO 14971 will ensure that a process is in place to address general risk management aspects related to medical devices, which are included in the Essential Requirements. However, because this is an international Standard, intended to be applicable in jurisdictions all over the world, it is not the primary goal of the standard to cover exactly any of the European Essential Requirements. Therefore, for all of the Essential Requirements, conformity is not entirely achieved by complying only with the requirements specified in this standard. Manufacturers and conformity assessment bodies will need to feed the Essential Requirements into the risk management process provided by the standard. Explanation on the correspondence of the standard and the Essential Requirements is included in Table ZB.1. Further explanation on content deviations between the standard and the ERs is provided below the table.

Table ZB.1 — Correspondence between this European Standard and Directive 90/385/EEC

<table>
<thead>
<tr>
<th>Clause(s)/subclause(s) of this EN</th>
<th>Essential Requirements (ERs) of Directive 90/385/EEC</th>
<th>Qualifying remarks/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-9</td>
<td>1</td>
<td>ER 1 is not directly covered by EN ISO 14971, since the standard does not provide requirements on design and manufacture. However, the standard provides a tool to generate the information that is a necessary preliminary step for a manufacturer to demonstrate that the device is in conformity with ER 1. For content deviations, see points 1, 2, 3 below.</td>
</tr>
<tr>
<td>ER</td>
<td>Coverage</td>
<td>Details</td>
</tr>
<tr>
<td>------</td>
<td>----------</td>
<td>---------</td>
</tr>
<tr>
<td>ER 3</td>
<td>Not covered</td>
<td>ER 3 is not directly covered by EN ISO 14971, since the standard does not apply the concept of ‘safety principles’ as intended in the AIMDD. However, the standard provides a tool to generate the information that is a necessary preliminary step for a manufacturer to demonstrate that the device is in conformity with ER 3.</td>
</tr>
<tr>
<td>ER 4</td>
<td>Not covered</td>
<td>ER 4 is not directly covered by EN ISO 14971, since the standard does not provide requirements on design, manufacture or packaging. However, the standard provides a tool to generate the information that is a necessary preliminary step for a manufacturer to demonstrate that the device is in conformity with ER 4.</td>
</tr>
<tr>
<td>ER 5</td>
<td>Covered</td>
<td>ER 5 is covered. However, for content deviations, see points 1, 2, 3, 4 below.</td>
</tr>
<tr>
<td>ER 6</td>
<td>Not covered</td>
<td>ER 6 is not directly covered by EN ISO 14971, since the standard does not provide requirements on design and construction, nor does it apply the concept of ‘safety principles’ as intended in the AIMDD. However, the standard provides a tool to generate the information that is a necessary preliminary step for a manufacturer to demonstrate that the device is in conformity with ER 6. For content deviations, see point 3 below.</td>
</tr>
<tr>
<td>ER 9</td>
<td>Only partly covered</td>
<td>ER 9 is only partly covered by EN ISO 14971, since the standard does not provide requirements on design and manufacture and does not cover performances and characteristics related thereto. Furthermore, it does not provide specific requirements on the items that must be paid particular attention. However, the standard provides a tool to generate the information that is a necessary preliminary step for a manufacturer to demonstrate that the device is in conformity with ER 9. For content deviations, see points 1 to 4 below.</td>
</tr>
</tbody>
</table>
Content deviations

The following aspects have been identified where the standard deviates or might be understood as deviating from the Essential Requirements:

1. Treatment of negligible risks:
   a) According to ISO 14971, the manufacturer may discard negligible risks.4
   b) However, Sections 1 and 6 of Annex I to Directive 90/385/EEC require that all risks, regardless of their dimension, need to be reduced as much as possible.
   c) Accordingly, the manufacturer must take all risks into account when assessing Sections 1 and 6 of Annex I to Directive 90/385/EEC.

2. Discretionary power of manufacturers as to the acceptability of risks:
   a) ISO 14971 seems to imply that manufacturers have the freedom to decide upon the threshold for risk acceptability5 and that only non-acceptable risks have to be integrated into the overall risk-benefit analysis.6
   b) However, Sections 1 and 6 of Annex I to Directive 90/385/EEC require that all risks have to be reduced as far as possible.
   c) Accordingly, the manufacturer may not apply any criteria of risk acceptability prior to applying Sections 1 and 6 of Annex I to Directive 90/385/EEC.

3. Risk reduction "as far as possible" versus "as low as reasonably practicable":
   a) D.8 of ISO 14971, referred to in 3.4, contains the concept of reducing risks "as low as reasonably practicable" (ALARP concept). The ALARP concept contains an element of economic consideration.
   b) However, various Essential Requirements require risks to be reduced "as far as possible" without there being room for economic considerations.
   c) Accordingly, manufacturers and Notified Bodies may not apply the ALARP concept with regard to economic considerations.

4. Discretion as to whether a risk-benefit analysis needs to take place:
   a) 6.5 of ISO 14971 says: "If the residual risk is not judged acceptable using the criteria established in the risk management plan and further risk control is not practicable, the manufacturer may gather and review data and literature to determine if the medical benefits of the intended use outweigh the residual risk." Clause 7 of ISO 14971 says: "If the overall residual risk is not judged acceptable using the criteria established in the risk management plan, the manufacturer may gather and review data and literature to determine if the medical benefits of the intended use outweigh the overall residual risk." Both quotes imply that an overall risk-benefit analysis does not need to take place if the overall residual risk is judged acceptable when using the criteria established in the risk management plan. Equally, D.6.1 says: "A risk-benefit analysis is not required by this International Standard for every risk."
   b) Section 5 of Annex I to Directive 90/385/EEC requires any side effects or undesirable conditions to "constitute acceptable risks when weighed against the performances intended", implying that an overall risk-benefit analysis must take place in any case, regardless of the application of criteria established in the management plan of the manufacturer.
   c) Accordingly, the manufacturer must undertake the risk-benefit analysis for the individual risk and the overall risk-benefit analysis (weighing all risks combined against the benefit) in all cases.

---

4 This is explicitly stated in D.8.2.

5 Sections 5, 6.4, 6.5, 7: reference to the criteria set-up in the management plan which is under the discretion of the manufacturer (see Sections 3.2, 3.4d)). See also D.4: "This International Standard does not specify acceptable risk. That decision is left to the manufacturer."

6 See D.6.1.
Conformity assessment procedures

EN ISO 14971 can also be used to support the following parts of conformity assessment procedures in the European Medical Devices Directives:

− an adequate description of results of the risk analysis (included in the risk management file, see 3.5 of EN ISO 14971:2012);
− an undertaking by the manufacturer to institute and keep up to date a systematic procedure to review experience gained from devices in the post-production phase and to implement appropriate means to apply any necessary corrective action (see Clause 9 of EN ISO 14971:2012).

NOTE Other and more detailed requirements are applicable to this aspect.

WARNING — Other requirements and other EU Directives may be applicable to a product falling within the scope of this standard.
Annex ZC  
(informative)

Relationship between this European Standard and Requirements of EU Directive 98/79/EC on In Vitro Diagnostic Medical Devices

This European Standard has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association to provide a means of conforming to Requirements of the New Approach Directive 98/79/EC on In Vitro Diagnostic Medical Devices.

Within the limits of the scope of this standard (Clause 1 of EN ISO 14971:2012), compliance with the clauses of this standard confers a presumption of conformity with requirements of that Directive and associated EFTA regulations, once this standard is cited in the Official Journal of the European Union under that Directive and has been implemented as a national standard in at least one Member State. This Annex ZC explains to which requirements, under which conditions and to what extent presumption of conformity can be claimed.

Whilst only a limited number of requirements is covered just by the application of this standard, authorities in charge of medical devices strongly recommend using this standard. The standard leads, according to experience of the authorities, to a higher degree of compliance with legal obligations.

EN ISO 14971:2012 provides a process for managing risks associated with medical devices. Because this standard describes an ongoing, lifecycle process applicable in part or in all to the Essential Requirements of Directive 98/79/EC on In Vitro Diagnostic Medical Devices, it is – very exceptionally – not meaningful to link individual clauses of the standard to specific corresponding Essential Requirements.

Compliance with all the normative clauses in EN ISO 14971 will ensure that a process is in place to address general risk management aspects related to medical devices, which are included in the Essential Requirements. However, because this is an International Standard, intended to be applicable in jurisdictions all over the world, it is not the primary goal of the standard to cover exactly any of the European Essential Requirements. Therefore, for all of the Essential Requirements, conformity is not entirely achieved by complying only with the requirements specified in this standard. Manufacturers and conformity assessment bodies will need to feed the Essential Requirements into the risk management process provided by the standard. Explanation on the correspondence of the standard and the Essential Requirements is included in Table ZC.1. Further explanation on content deviations between the standard and the ERs is provided below the table.

Table ZC.1 — Correspondence between this European Standard and Directive 98/79/EEC

<table>
<thead>
<tr>
<th>Clause(s)/subclause(s) of this EN</th>
<th>Essential Requirements (ERs) of Directive 98/79/EC</th>
<th>Qualifying remarks/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-9</td>
<td>A.1</td>
<td>ER A.1 is not directly covered by EN ISO 14971, since the standard does not provide requirements on design and manufacture. However, the standard provides a tool to generate the information that is a necessary preliminary step for a manufacturer to demonstrate that the device is in conformity with ER A.1. For content deviations, see points 1, 2, 3, 4 below.</td>
</tr>
<tr>
<td>1-9</td>
<td>A.2</td>
<td>- The second sentence of ER A.2 is partly covered by 6.2. For content</td>
</tr>
</tbody>
</table>
|   |   | deviations, see points 1, 2, 3, 5, 6, 7 below.  
|   |   | - The other parts of ER A.2 are not directly covered by EN ISO 14971, since the standard does not provide requirements on design and construction, nor does it apply the concept of ‘safety principles’ as intended in the IVDD. However, the standard provides a tool to generate the information that is a necessary preliminary step for a manufacturer to demonstrate that the device is in conformity with ER A.2.  
|   | 1-9 A.4  | ER A.4 is not directly covered by EN ISO 14971, since the standard does not apply the concept of ‘safety principles’ as intended in the IVDD. However, the standard provides a tool to generate the information that is a necessary preliminary step for a manufacturer to demonstrate that the device is in conformity with ER A.4.  
|   | 1-9 A.5  | ER A.5 is not directly covered by EN ISO 14971, since the standard does not provide requirements on design, manufacture or packaging. However, the standard provides a tool to generate the information that is a necessary preliminary step for a manufacturer to demonstrate that the device is in conformity with ER A.5.  
|   | 1-9 B.1.1 | ER B.1.1 is only partly covered by EN ISO 14971, since the standard does not provide requirements on design and manufacture and does not cover performances and characteristics related thereto. Furthermore, it does not provide specific requirements on the items that must be paid particular attention. However, the standard provides a tool to generate the information that is a necessary preliminary step for a manufacturer to demonstrate that the device is in conformity with ER B.1.1. For content deviations, see points 1 to 7 below.  

Content deviations

The following aspects have been identified where the standard deviates or might be understood as deviating from the Essential Requirements:

1. Treatment of negligible risks:
   a) According to ISO 14971, the manufacturer may discard negligible risks.7
   b) However, Sections A.1 and A.2 of Annex I to Directive 98/79/EC require that all risks, regardless of their dimension, need to be reduced as much as possible and need to be balanced, together with all other risks, against the benefit of the device.
   c) Accordingly, the manufacturer must take all risks into account when assessing Sections A.1 and A.2 of Annex I to Directive 98/79/EC.

2. Discretionary power of manufacturers as to the acceptability of risks:
   a) ISO 14971 seems to imply that manufacturers have the freedom to decide upon the threshold for risk acceptability8 and that only non-acceptable risks have to be integrated into the overall risk-benefit analysis9.
   b) However, Sections A.1 and A.2 of Annex I to Directive 98/79/EC require that all risks have to be reduced as far as possible and that all risks combined, regardless of any "acceptability" assessment, need to be balanced, together with all other risks, against the benefit of the device.
   c) Accordingly, the manufacturer may not apply any criteria of risk acceptability prior to applying Sections A.1 and A.2 of Annex I to Directive 98/79/EC.

3. Risk reduction "as far as possible" versus "as low as reasonably practicable":
   a) D.8 to ISO 14971, referred to in 3.4, contains the concept of reducing risks "as low as reasonably practicable" (ALARP concept). The ALARP concept contains an element of economic consideration.
   b) However, the first indent of Section A.2 of Annex I to Directive 98/79/EC and various particular Essential Requirements require risks to be reduced "as far as possible" without there being room for economic considerations.
   c) Accordingly, manufacturers and Notified Bodies may not apply the ALARP concept with regard to economic considerations.

4. Discretion as to whether a risk-benefit analysis needs to take place:
   a) 6.5 of ISO 14971 says: "If the residual risk is not judged acceptable using the criteria established in the risk management plan and further risk control is not practicable, the manufacturer may gather and review data and literature to determine if the medical benefits of the intended use outweigh the residual risk." Clause 7 of ISO 14971 says: "If the overall residual risk is not judged acceptable using the criteria established in the risk management plan, the manufacturer may gather and review data and literature to determine if the medical benefits of the intended use outweigh the overall residual risk." Both quotes imply that an overall risk-benefit analysis does not need to take place if the overall residual risk is judged acceptable when using the criteria established in the risk management plan.
   b) According to Section A.1 of Annex I to Directive 98/79/EC, an overall risk-benefit analysis must take place in any case, regardless of the application of criteria established in the management plan of the manufacturer.
   c) Accordingly, the manufacturer must undertake the overall risk-benefit analysis (weighing all risks combined against the benefit) in all cases.

7 This is explicitly stated in D.8.2.
8 Sections 5, 6.4, 6.5, 7: reference to the criteria set-up in the management plan which is under the discretion of the manufacturer (see Sections 3.2, 3.4d)). See also D.4: "This International Standard does not specify acceptable risk. That decision is left to the manufacturer."
9 See D.6.1.
5. Discretion as to the risk control options/measures:

a) 6.2 of ISO 14971 obliges the manufacturer to "use one or more of the following risk control options in the priority order listed: (a) inherent safety by design; (b) protective measures in the medical device itself or in the manufacturing process; (c) information for safety" and leaves a discretion as to the application of these three options: shall the second or third control option still be used when the first was used? 6.4 indicates that further risk control measures do not need to be taken if, after applying one of the control options, the risk is judged acceptable according to the criteria of the risk management plan.

b) However, the second sentence of Section A.2 of Annex I to Directive 98/79/EC requests "to conform to safety principles, taking account of the generally acknowledged state of the art" and "to select the most appropriate solutions" by applying cumulatively what has been called "control options" or "control mechanisms" in the standard.

c) Accordingly, the manufacturer must apply all the "control options" and may not stop his endeavours if the first or the second control option has reduced the risk to an "acceptable level" (unless the additional control option(s) do(es) not improve the safety).

6. Deviation as to the first risk control option:

a) 6.2 of ISO 14971 obliges the manufacturer to "use one or more of the following risk control options in the priority order listed: (a) inherent safety by design …" without determining what is meant by this term.

b) However, the first indent of the second sentence of Section A.2 of Annex I to Directive 98/79/EC requires to "eliminate or reduce risks as far as possible (inherently safe design and construction)".

c) Accordingly, as the Directive is more precise than the standard, manufacturers must apply the former and cannot rely purely on the application of the standard.

7. Information of the users influencing the residual risk:

a) The residual risk is in 2.15 and in 6.4 of ISO 14971 defined as the risk remaining after application of the risk control measures. 6.2 of ISO 14971 regards "information for safety" to be a control option.

b) However, the last indent of Section A.2 of Annex I to Directive 98/79/EC says that users shall be informed about the residual risks. This indicates that, according to Annex I to Directive 98/79/EC and contrary to the concept of the standard, the information given to the users does not reduce the (residual) risk any further.

c) Accordingly, manufacturers shall not attribute any additional risk reduction to the information given to the users.

Conformity assessment procedures

EN ISO 14971 can also be used to support the following parts of conformity assessment procedures in the European Medical Devices Directives:

- an adequate description of results of the risk analysis (included in the risk management file, see 3.5 of EN ISO 14971:2012);

- an undertaking by the manufacturer to institute and keep up to date a systematic procedure to review experience gained from devices in the post-production phase and to implement appropriate means to apply any necessary corrective action (see Clause 9 of EN ISO 14971:2012).

NOTE Other and more detailed requirements are applicable to this aspect.

WARNING — Other requirements and other EU Directives may be applicable to a product falling within the scope of this standard.
# Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreword</td>
<td>iv</td>
</tr>
<tr>
<td>Introduction</td>
<td>v</td>
</tr>
<tr>
<td>1 Scope</td>
<td>1</td>
</tr>
<tr>
<td>2 Terms and definitions</td>
<td>1</td>
</tr>
<tr>
<td>3 General requirements for risk management</td>
<td>5</td>
</tr>
<tr>
<td>3.1 Risk management process</td>
<td>5</td>
</tr>
<tr>
<td>3.2 Management responsibilities</td>
<td>7</td>
</tr>
<tr>
<td>3.3 Qualification of personnel</td>
<td>7</td>
</tr>
<tr>
<td>3.4 Risk management plan</td>
<td>7</td>
</tr>
<tr>
<td>3.5 Risk management file</td>
<td>8</td>
</tr>
<tr>
<td>4 Risk analysis</td>
<td>8</td>
</tr>
<tr>
<td>4.1 Risk analysis process</td>
<td>8</td>
</tr>
<tr>
<td>4.2 Intended use and identification of characteristics related to the safety of the medical device</td>
<td>9</td>
</tr>
<tr>
<td>4.3 Identification of hazards</td>
<td>9</td>
</tr>
<tr>
<td>4.4 Estimation of the risk(s) for each hazardous situation</td>
<td>9</td>
</tr>
<tr>
<td>5 Risk evaluation</td>
<td>10</td>
</tr>
<tr>
<td>6 Risk control</td>
<td>11</td>
</tr>
<tr>
<td>6.1 Risk reduction</td>
<td>11</td>
</tr>
<tr>
<td>6.2 Risk control option analysis</td>
<td>11</td>
</tr>
<tr>
<td>6.3 Implementation of risk control measure(s)</td>
<td>11</td>
</tr>
<tr>
<td>6.4 Residual risk evaluation</td>
<td>12</td>
</tr>
<tr>
<td>6.5 Risk/benefit analysis</td>
<td>12</td>
</tr>
<tr>
<td>6.6 Risks arising from risk control measures</td>
<td>12</td>
</tr>
<tr>
<td>6.7 Completeness of risk control</td>
<td>12</td>
</tr>
<tr>
<td>7 Evaluation of overall residual risk acceptability</td>
<td>13</td>
</tr>
<tr>
<td>8 Risk management report</td>
<td>13</td>
</tr>
<tr>
<td>9 Production and post-production information</td>
<td>13</td>
</tr>
<tr>
<td>Annex A (informative) Rationale for requirements</td>
<td>15</td>
</tr>
<tr>
<td>Annex B (informative) Overview of the risk management process for medical devices</td>
<td>23</td>
</tr>
<tr>
<td>Annex C (informative) Questions that can be used to identify medical device characteristics that could impact on safety</td>
<td>25</td>
</tr>
<tr>
<td>Annex D (informative) Risk concepts applied to medical devices</td>
<td>32</td>
</tr>
<tr>
<td>Annex E (informative) Examples of hazards, foreseeable sequences of events and hazardous situations</td>
<td>49</td>
</tr>
<tr>
<td>Annex F (informative) Risk management plan</td>
<td>54</td>
</tr>
<tr>
<td>Annex G (informative) Information on risk management techniques</td>
<td>56</td>
</tr>
<tr>
<td>Annex H (informative) Guidance on risk management for in vitro diagnostic medical devices</td>
<td>60</td>
</tr>
<tr>
<td>Annex I (informative) Guidance on risk analysis process for biological hazards</td>
<td>76</td>
</tr>
<tr>
<td>Annex J (informative) Information for safety and information about residual risk</td>
<td>78</td>
</tr>
<tr>
<td>Bibliography</td>
<td>80</td>
</tr>
</tbody>
</table>
Introduction

The requirements contained in this International Standard provide manufacturers with a framework within which experience, insight and judgment are applied systematically to manage the risks associated with the use of medical devices.

This International Standard was developed specifically for medical device/system manufacturers using established principles of risk management. For other manufacturers, e.g., in other healthcare industries, this International Standard could be used as informative guidance in developing and maintaining a risk management system and process.

This International Standard deals with processes for managing risks, primarily to the patient, but also to the operator, other persons, other equipment and the environment.

As a general concept, activities in which an individual, organization or government is involved can expose those or other stakeholders to hazards which can cause loss of or damage to something they value. Risk management is a complex subject because each stakeholder places a different value on the probability of harm occurring and its severity.

It is accepted that the concept of risk has two components:

a) the probability of occurrence of harm;

b) the consequences of that harm, that is, how severe it might be.

The concepts of risk management are particularly important in relation to medical devices because of the variety of stakeholders including medical practitioners, the organizations providing health care, governments, industry, patients and members of the public.

All stakeholders need to understand that the use of a medical device entails some degree of risk. The acceptability of a risk to a stakeholder is influenced by the components listed above and by the stakeholder's perception of the risk. Each stakeholder's perception of the risk can vary greatly depending upon their cultural background, the socio-economic and educational background of the society concerned, the actual and perceived state of health of the patient, and many other factors. The way a risk is perceived also takes into account, for example, whether exposure to the hazard seems to be involuntary, avoidable, from a man-made source, due to negligence, arising from a poorly understood cause, or directed at a vulnerable group within society. The decision to use a medical device in the context of a particular clinical procedure requires the residual risks to be balanced against the anticipated benefits of the procedure. Such judgments should take into account the intended use, performance and risks associated with the medical device, as well as the risks and benefits associated with the clinical procedure or the circumstances of use. Some of these judgments can be made only by a qualified medical practitioner with knowledge of the state of health of an individual patient or the patient's own opinion.

As one of the stakeholders, the manufacturer makes judgments relating to safety of a medical device, including the acceptability of risks, taking into account the generally accepted state of the art, in order to determine the suitability of a medical device to be placed on the market for its intended use. This International Standard specifies a process through which the manufacturer of a medical device can identify hazards associated with a medical device, estimate and evaluate the risks associated with these hazards, control these risks, and monitor the effectiveness of that control.

For any particular medical device, other International Standards could require the application of specific methods for managing risk.
Medical devices — Application of risk management to medical devices

1 Scope

This International Standard specifies a process for a manufacturer to identify the hazards associated with medical devices, including in vitro diagnostic (IVD) medical devices, to estimate and evaluate the associated risks, to control these risks, and to monitor the effectiveness of the controls.

The requirements of this International Standard are applicable to all stages of the life-cycle of a medical device.

This International Standard does not apply to clinical decision making.

This International Standard does not specify acceptable risk levels.

This International Standard does not require that the manufacturer have a quality management system in place. However, risk management can be an integral part of a quality management system.

2 Terms and definitions

For the purposes of this document, the following terms and definitions apply:

2.1 accompanying document

document accompanying a medical device and containing information for those accountable for the installation, use and maintenance of the medical device, the operator or the user, particularly regarding safety

NOTE Adapted from IEC 60601-1:2005, definition 3.4.

2.2 harm

physical injury or damage to the health of people, or damage to property or the environment

[ISO/IEC Guide 51:1999, definition 3.3]

2.3 hazard

potential source of harm


2.4 hazardous situation

circumstance in which people, property, or the environment are exposed to one or more hazard(s)


NOTE See Annex E for an explanation of the relationship between “hazard” and “hazardous situation”.

© ISO 2007 – All rights reserved